Sermorelin
Research OnlyA GHRH analog that was FDA-approved for pediatric GH deficiency. Now discontinued commercially but established safety and efficacy profile exists.
Geref · GRF 1-29 · GHRH(1-29)NH2
32 human studies
- Preclinical
- 20%
- Human research
- 80%
Based on 40 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
Sermorelin is the biologically active 1-29 amino acid fragment of endogenous GHRH (Growth Hormone-Releasing Hormone). It stimulates the pituitary gland to release growth hormone through receptor-mediated signaling, preserving natural feedback mechanisms.
How It Works (Simplified)
Sermorelin acts as a “release signal” that tells your pituitary gland to produce growth hormone:
Binds to GHRH receptors on pituitary somatotroph cells, triggering the cAMP/PKA signaling cascade that initiates GH synthesis and release.
Stimulates natural pulsatile GH secretion rather than constant elevation, preserving your body’s feedback systems and circadian rhythm.
Acts on CNS GHRH receptors to promote slow-wave sleep independently of peripheral GH effects, enhancing restorative deep sleep phases.
Key Research: Thorner M et al. (USA, 1996) demonstrated 74% growth acceleration in GH-deficient children in the pivotal Geref International Study. PMID:8772599
Important Limitations
- Requires functional pituitary gland to produce effects
- Short half-life (10-20 minutes) necessitates daily administration
- Effects may diminish in severe pituitary damage or destruction
- Was FDA-approved but discontinued in 2008 for business reasons (not safety concerns)
Reported positives
- Improved sleep quality frequently cited as primary benefit
- Gradual body composition improvements reported
- Well-tolerated with fewer side effects than direct GH
- Available through anti-aging clinics with medical supervision
Reported negatives
- Effects subtle and require months of consistent use
- Injection site reactions and irritation
- Fasting requirements for optimal timing
- Efficacy decreases with age as GH receptors decline
“One of the earliest peptides prescribed in anti-aging clinics. Community views it as a milder, safer GH alternative.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
GH release begins within 15-30 minutes of subcutaneous injection. Peak GH typically occurs 30-60 minutes post-injection. Sermorelin produces a physiological pulsatile GH response.
Based on clinical trial data: Daily administration establishes regular GH pulsatility. IGF-1 levels begin to rise. Some patients report improved sleep quality early in treatment.
Clinical studies in GH-deficient children showed growth velocity improvements over 6-12 months. In adult studies, IGF-1 levels approached normal ranges with continued use.
Growth velocity improvements documented in pediatric GHD trials. Body composition changes (increased lean mass, reduced fat) may become apparent with continued use.
Long-term pediatric studies showed sustained growth improvements. Sermorelin was FDA-approved for pediatric GHD before discontinuation in 2008 due to manufacturing (not safety) issues.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Ipamorelin
SynergisticGHRH+GHRP synergy well-documented in literature. Sermorelin (GHRH) combined with ipamorelin (GHRP) produces greater GH release than either alone through complementary receptor pathways.
GHRP-6
SynergisticClassic synergistic combination used in research. GHRH amplifies GH pulse while GHRP initiates release.
GHRP-2
SynergisticComplementary mechanisms through GHRH and ghrelin receptor pathways produce synergistic GH secretion.
Semaglutide
CautionGH secretagogues may affect glucose metabolism. Monitor in diabetic patients.
CJC-1295
AvoidBoth are GHRH analogs with identical mechanism of action. Use one or the other.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Sermorelin
Related Peptides
Follistatin
FST · FS-344 · FS-315 +1
Follistatin is an endogenous protein that binds activin and myostatin. Small human AAV gene-transfer studies and trials of an engineered follistatin-based protein do not establish clinical benefit or safety for native follistatin protein administration.
GHRP-2
Growth Hormone Releasing Peptide-2 · Pralmorelin · KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6 · SKF-110679 · Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG · Choriogonadotropin · Pregnyl +5
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin · HEX · Growth Hormone Releasing Hexapeptide +2
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
HMG
Human Menopausal Gonadotropin · Menotropins · hMG +4
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.
Compared With
5 comparisonsConditions Studied
5 entries- Sermorelin for Growth Hormone Deficiency Sermorelin was FDA-approved for pediatric growth hormone deficiency, making it one of few GHRH analogs with established regulatory…
- Sermorelin for Anti-Aging Sermorelin has been extensively studied for age-related GH decline (somatopause). NIH research demonstrated that GHRH(1-29) revers…
- Sermorelin for Sleep Improvement Multiple studies have demonstrated that GHRH administration enhances slow-wave sleep (SWS), the restorative deep sleep phase. Germ…
- Sermorelin for Cognitive Function A 20-week randomized controlled trial demonstrated that sermorelin treatment increased brain GABA levels in all measured regions a…
- Sermorelin for Body Composition Clinical trials have shown that GHRH therapy can improve body composition in older adults. A 20-week randomized trial in healthy o…